According to the U.S. Food and Drug Administration (FDA), drug maker Pfizer Inc. has halted the development of its experimental cholesterol drug torcetrapib, because a number of patients taking the drug in clinical trials experienced an increase in heart problems. The director of the FDA’s Center for Drug Evaluation and Research also announced that similar cholesterol drugs (called “CETP inhibitors”) currently in development will undergo increased scrutiny.
- Read the FDA Press Release
- Statement from Pfizer, Inc.
- Defective and Dangerous Products
- You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help
- Meeting with a lawyer can help you understand your options and how to best protect your rights. Visit our attorney directory to find a lawyer near you who can help.
- Or contact an attorney near you:
- SPONSORED
You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help
Civil Rights
Block on Trump’s Asylum Ban Upheld by Supreme Court
Criminal
Judges Can Release Secret Grand Jury Records
Politicians Can’t Block Voters on Facebook, Court Rules
